Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05960786 · ClinicalTrials.gov registry record · NA
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
A NA study, sponsored by Otolith Labs.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
NCT05960786: Completed NA study, sponsored by Otolith Labs.
NCT05960786 is a NA study that has completed, run by Otolith Labs. The registered enrollment target is 109 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05960786, a NA study, has completed, sponsored by Otolith Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
Study Summary
The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vestibular vertigo. The main question\[s\] it aims to answer are: * Within an episode, is there a significant difference between the randomized study devices at the individual timepoints during the vertigo episode? * Within an episode, is there evidence of quantitative treatment at each individual timepoint during the vertigo episode? Participants will be: * Enrolled up to 49 days; 14 days in Baseline Phase (no device) and 21 days in Treatment Phase (study device) for Study Arm 1 or 28 days in Treatment Phase (study device) for Study Arm 2 * Randomized and stratified into groups based on diagnosis to be assigned a study device * Asked to use the study device as instructed by the study coordinator * Asked to download a study app to submit daily diaries regarding their symptoms and use of device, and to participate in tele-health visits with study coordinators * Asked to provide their vertigo diagnosis from their physician * Compensated for their participation Researchers will compare the randomized groups to see which groups respond better to which device.
Primary Outcome
Change in participant response to "How severe is your vertigo right now?" during vertigo episodes, compared to responses in baseline phase
Interventions
- DEVICE Otoband Experimental
- DEVICE Otoband Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2023-12-07 |
| Phase | NA |
What the finished NCT05960786 record still lists
NCT05960786 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Otoband Experimental is the first listed.
NCT05960786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05960786 about?
NCT05960786 is a clinical study titled "Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand". The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vestibular vertigo. The main question\[s\] it aims to answer are: * Within an episode, is there a significant differ...
What is the current status of trial NCT05960786?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2023-02-02. Estimated completion is 2023-12-07.
What interventions are being tested in trial NCT05960786?
The interventions under investigation include: Otoband Experimental (DEVICE), Otoband Sham (DEVICE).
Who is sponsoring clinical trial NCT05960786?
This trial is sponsored by Otolith Labs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05960786's enrollment target sits among peer trials
109 825th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI